Kleiner Perkins Caufield & Byers
Kleiner Perkins Caufield & Byers (www.kpcb.com) is an active venture capital partnership headquartered in the San Francisco Bay Area with a large capital base for investment. Since 1972, the company has invested in over 575 technology companies which have accrued market valuations exceeding $500 billion and employ more than 400,000. We began our commitment to the healthcare field in the late 1970’s with seed financings and assistance to both Genentech and Hybritech. Since then, KPCB has helped fund and grow over 85 biotechnology, medical device and related life science ventures. KPCB’s commitment to Personalized Medicine is based on the opportunity to be involved with new companies developing and translating breakthrough technologies to address unmet medical needs, improve medical outcomes of emerging and existing therapies, and reduce overall healthcare costs. Examples are Genomic Health, XDx, CardioDX, Tethys, Crescendo, Veractye and a variety of targeted therapy drug and device companies.